ESPR · Categories · Form 4

ESPR - SEC Form 4 insider transactions

Esperion Therapeutics Inc. (ESPR) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for ESPR

• 8d
  Director Thompson John Craig was granted 79,873 shares (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 8d
  Director Shepard Jay was granted 79,873 shares, increasing direct ownership by 94% to 164,472 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 8d
  Director Hoffman Robert E. was granted 79,873 shares, increasing direct ownership by 1,513% to 85,153 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 8d
  Director Fischer Seth H. Z. was granted 79,873 shares, increasing direct ownership by 131% to 141,023 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 8d
  Director Carroll J Martin was granted 79,873 shares, increasing direct ownership by 82% to 177,523 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 83d
  SEC Form 4 filed by Koenig Sheldon L.

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 83d
  SEC Form 4 filed by Looker Benjamin

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 83d
  SEC Form 4 filed by Halladay Benjamin

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 85d
  Chief Legal Officer Looker Benjamin was granted 300,840 shares, increasing direct ownership by 78% to 685,056 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 85d
  President and CEO Koenig Sheldon L. was granted 723,760 shares, increasing direct ownership by 49% to 2,198,277 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 85d
  Chief Financial Officer Halladay Benjamin was granted 247,430 shares, increasing direct ownership by 52% to 720,026 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 138d
  General Counsel Looker Benjamin sold $4,868 worth of shares (1,689 units at $2.88), decreasing direct ownership by 0.44% to 384,216 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 172d
  President and CEO Koenig Sheldon L. sold $177,200 worth of shares (48,244 units at $3.67), decreasing direct ownership by 3% to 1,470,587 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 172d
  Chief Financial Officer Halladay Benjamin sold $26,905 worth of shares (7,337 units at $3.67), decreasing direct ownership by 2% to 467,525 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 172d
  General Counsel Looker Benjamin sold $23,898 worth of shares (6,517 units at $3.67), decreasing direct ownership by 2% to 385,905 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 182d
  Chief Commercial Officer Harlow John B. Jr. was granted 424,536 shares (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 264d
  General Counsel Looker Benjamin sold $17,573 worth of shares (6,267 units at $2.80), decreasing direct ownership by 2% to 393,670 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 264d
  President and CEO Koenig Sheldon L. sold $79,254 worth of shares (28,427 units at $2.79), decreasing direct ownership by 2% to 1,518,831 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 264d
  Chief Financial Officer Halladay Benjamin sold $19,785 worth of shares (7,046 units at $2.81), decreasing direct ownership by 1% to 474,862 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 326d
  General Counsel Looker Benjamin sold $1,470 worth of shares (1,304 units at $1.13), decreasing direct ownership by 0.32% to 399,937 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 326d
  Chief Financial Officer Halladay Benjamin sold $12 worth of shares (11 units at $1.11), decreasing direct ownership by 0.00% to 474,462 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 342d
  SEC Form 4 filed by Director Thompson John Craig

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 355d
  General Counsel Looker Benjamin sold $7,398 worth of shares (6,422 units at $1.15), decreasing direct ownership by 2% to 401,241 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 355d
  President and CEO Koenig Sheldon L. sold $33,796 worth of shares (30,474 units at $1.11), decreasing direct ownership by 2% to 1,541,488 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 355d
  Chief Financial Officer Halladay Benjamin sold $8,328 worth of shares (7,229 units at $1.15), decreasing direct ownership by 2% to 474,473 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 372d
  Director Carroll J Martin was granted 33,000 shares, increasing direct ownership by 51% to 97,650 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 372d
  Director Fischer Seth H. Z. was granted 33,000 shares, increasing direct ownership by 117% to 61,150 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 372d
  Director Hoffman Robert E. was granted 5,280 shares (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 372d
  Director Rocamboli Stephen was granted 33,000 shares, increasing direct ownership by 91% to 69,261 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 372d
  Director Shepard Jay was granted 33,000 shares, increasing direct ownership by 64% to 84,599 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 372d
  SEC Form 4 filed by Director Vitullo Nicole

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 372d
  SEC Form 4 filed by Director Woody Tracy M

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 414d
  Chief Commercial Officer Warren Eric sold $106 worth of shares (108 units at $0.98), decreasing direct ownership by 0.03% to 370,218 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 414d
  Chief Financial Officer Halladay Benjamin sold $8 worth of shares (8 units at $0.96), decreasing direct ownership by 0.00% to 481,702 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 433d
  SEC Form 4 filed by Director Hoffman Robert E.

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 447d
  Chief Financial Officer Halladay Benjamin sold $5,242 worth of shares (3,535 units at $1.48), decreasing direct ownership by 0.73% to 481,710 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 447d
  Chief Commercial Officer Warren Eric sold $3,618 worth of shares (2,433 units at $1.49), decreasing direct ownership by 0.65% to 370,326 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 447d
  President and CEO Koenig Sheldon L. sold $19,623 worth of shares (13,047 units at $1.50), decreasing direct ownership by 0.82% to 1,571,962 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 448d
  President and CEO Koenig Sheldon L. was granted 840,000 shares, increasing direct ownership by 113% to 1,585,009 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 448d
  Chief Financial Officer Halladay Benjamin was granted 238,000 shares, increasing direct ownership by 96% to 485,245 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 448d
  Chief Commercial Officer Warren Eric was granted 213,000 shares, increasing direct ownership by 133% to 372,759 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 448d
  General Counsel Looker Benjamin was granted 224,000 shares, increasing direct ownership by 122% to 407,663 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 473d
  Chief Commercial Officer Warren Eric sold $446 worth of shares (239 units at $1.87), decreasing direct ownership by 0.15% to 159,759 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 473d
  Chief Financial Officer Halladay Benjamin sold $20 worth of shares (11 units at $1.86), decreasing direct ownership by 0.00% to 240,671 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 503d
  Chief Financial Officer Halladay Benjamin sold $20 worth of shares (9 units at $2.27), decreasing direct ownership by 0.00% to 240,682 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 503d
  Chief Commercial Officer Warren Eric sold $278 worth of shares (123 units at $2.26), decreasing direct ownership by 0.08% to 159,998 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 537d
  Chief Financial Officer Halladay Benjamin sold $7,866 worth of shares (3,245 units at $2.42), decreasing direct ownership by 1% to 240,691 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 537d
  Chief Commercial Officer Warren Eric sold $5,426 worth of shares (2,234 units at $2.43), decreasing direct ownership by 1% to 160,121 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 537d
  President and CEO Koenig Sheldon L. sold $30,694 worth of shares (12,447 units at $2.47), decreasing direct ownership by 2% to 739,819 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 565d
  Chief Commercial Officer Warren Eric sold $427 worth of shares (197 units at $2.17), decreasing direct ownership by 0.12% to 162,355 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 599d
  Chief Commercial Officer Warren Eric sold $227 worth of shares (107 units at $2.12), decreasing direct ownership by 0.07% to 162,552 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 629d
  President and CEO Koenig Sheldon L. sold $26,132 worth of shares (14,550 units at $1.80), decreasing direct ownership by 2% to 752,266 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 629d
  Chief Commercial Officer Warren Eric sold $4,650 worth of shares (2,608 units at $1.78), decreasing direct ownership by 2% to 162,659 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 658d
  Chief Commercial Officer Warren Eric sold $411 worth of shares (211 units at $1.95), decreasing direct ownership by 0.13% to 165,267 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 690d
  Chief Commercial Officer Warren Eric sold $279 worth of shares (108 units at $2.59), decreasing direct ownership by 0.07% to 165,478 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 690d
  Chief Medical Officer Foody Joanne M. sold $2,383 worth of shares (917 units at $2.60), decreasing direct ownership by 0.33% to 272,862 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 719d
  Chief Medical Officer Foody Joanne M. sold $9,418 worth of shares (3,285 units at $2.87), decreasing direct ownership by 1% to 273,779 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 719d
  Chief Commercial Officer Warren Eric sold $7,254 worth of shares (2,540 units at $2.86), decreasing direct ownership by 2% to 165,586 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 746d
  Carroll J Martin was granted 23,000 shares, increasing direct ownership by 55% to 64,650 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
• 746d
  Fischer Seth H. Z. was granted 23,000 shares, increasing direct ownership by 447% to 28,150 units (SEC Form 4)

  4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)

Other ESPR categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends